Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Annals of Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 2193613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomised double blind controlled trial of cyclosporin in multiple sclerosis.

  1989cited by this paper
• Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis.

  1988cited by this paper
• HLA-DP antigens are involved in the susceptibility to multiple sclerosis.

  1988cited by this paper
• Systemic Hypertension Associated with Cyclosporine: A Review

  1988cited by this paper
• Magnetic Resonance Imaging in the Assessment of Disease Activity in Multiple Sclerosis

  1988cited by this paper
• Cancers after cyclosporine therapy.

  1988cited by this paper
• Cyclosporine--mechanism of action.

  1988cited by this paper
• Optimizing cyclosporine therapy: dose, levels, and monitoring.

  1988cited by this paper
• Interferon-gamma and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions.

  1988cited by this paper
• Cyclosporine versus azathioprine in the long‐term treatment of multiple sclerosis—results of the german multicenter study

  1988cited by this paper
• Mechanisms of action of cyclosporine: effect on cells of the immune system and on subcellular events in T cell activation.

  1988cited by this paper
• Serial immune evaluation of cyclosporine- and placebo-treated multiple sclerosis patients.

  1988cited by this paper
• T-lymphocyte inhibition by cyclosporine. Potential mechanisms of action.

  1987cited by this paper
• The Natural History of Multiple Sclerosis

  1987cited by this paper
• Autoimmunity in Demyelinating Diseases

  1987cited by this paper
• T cell subsets in multiple sclerosis. Gradients at plaque borders and differences in nonplaque regions.

  1987cited by this paper
• Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody.

  1987cited by this paper
• A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.

  1987cited by this paper
• Treatment of multiple sclerosis with gamma interferon

  1987cited by this paper
• T Cells in Multiple Sclerosis and Inflammatory Central Nervous System Diseases

  1987cited by this paper
• Loss of patients in clinical trials that measure long-term survival following myocardial infarction.

  1986cited by this paper
• Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis

  1986cited by this paper
• Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions

  1986cited by this paper
• Activated suppressor cell dysfunction in progressive multiple sclerosis.

  1986cited by this paper
• Cyclosporine and the immune response: basic aspects.

  1986cited by this paper
• The basis of intra‐blood‐brain‐barrier IgG synthesis

  1985cited by this paper
• Selective loss of a subset of T helper cells in active multiple sclerosis.

  1985cited by this paper
• Use of cyclosporine in neurological autoimmune disease?

  1985cited by this paper
• Renal function in patients with autoimmune diseases treated with cyclosporine.

  1985cited by this paper
• Side effects of systemic cyclosporine in patients not undergoing transplantation.

  1984cited by this paper
• Criteria and uses of the Minimal Record of Disability in multiple sclerosis

  1984cited by this paper
• Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

  1984cited by this paper
• Cyclosporine: a new immunosuppressive agent for organ transplantation.

  1984cited by this paper
• Association between cyclosporin neurotoxicity and hypomagnesaemia.

  1984cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages.

  1983cited by this paper
• The influence of cyclosporin A on the development of actively induced and passively transferred experimental allergic encephalomyelitis.

  1983cited by this paper
• Treatment of intraocular inflammatory disease with cyclosporin A.

  1983cited by this paper
• Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

  1983cited by this paper
• Analysis of covariance using the rank transformation.

  1982cited by this paper
• Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis.

  1982cited by this paper
• The incidence and prevalence of reported multiple sclerosis

  1981cited by this paper
• Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation.

  1981cited by this paper
• Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis.

  1978cited by this paper
• Some thoughts on clinical trials, especially problems of multiplicity.

  1977cited by this paper
• Double-blind Trial of Linoleate Supplementation of the Diet in Multiple Sclerosis

  1973cited by this paper
• Cooperative study in the evaluation of therapy in multiple sclerosis

  1970cited by this paper
• Cooperative study in the evaluation of therapy in multiple sclerosis; ACTH vs placebo in acute exacerbations

  1968cited by this paper

• Inflammation and Immunomodulation in Cerebral X-linked Adrenoleukodystrophy: Review of Pathology and Interventions

  2025cites this paper
• Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk

  2025cites this paper
• Genetic susceptibility and causal pathway analysis of eye disorders coexisting in multiple sclerosis

  2024cites this paper
• The Development of the Combination Drug Leukovir® Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.

  2023cites this paper
• Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

  2022cites this paper
• Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: a systematic review and meta-analysis of 43 randomized placebo-controlled trials

  2020cites this paper
• Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis

  2019cites this paper
• Can We Treat Secondary Progressive Multiple Sclerosis Now?

  2019cites this paper
• Diagnosis and Management of Progressive Multiple Sclerosis

  2019cites this paper
• Disease-Modifying Treatment in Progressive Multiple Sclerosis

  2018cites this paper
• Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis

  2018cites this paper
• Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials

  2018cites this paper
• Treatment of progressive multiple sclerosis: Challenges and promising perspectives.

  2018cites this paper
• Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis

  2017cites this paper
• Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives

  2017cites this paper
• Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis

  2016cites this paper
• Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis

  2016cites this paper
• Progressive multiple sclerosis.

  2015cites this paper
• Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis*

  2015cites this paper
• Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

  2015cites this paper
• Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review

  2015cites this paper
• Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

  2013cites this paper
• Immunotherapy of Multiple Sclerosis

  2013cites this paper
• Protective effect of folic acid on cyclosporine‐induced bone loss in rats

  2012cites this paper
• Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application.

  2011cites this paper
• The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy

  2010cites this paper
• Effect of cyclosporine on blood pressure.

  2010cites this paper
• Nocebo effects in multiple sclerosis trials: a meta-analysis

  2010cites this paper
• Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies.

  2009cites this paper
• [Multiple sclerosis--symptoms, diagnosis and treatment].

  2009cites this paper
• Living donor kidney transplantation without transmission of multiple sclerosis after 10 years.

  2009cites this paper
• [Approaches to the treatment of malignant and progressive multiple sclerosis].

  2009cites this paper
• Medication induced gingival overgrowth.

  2008cites this paper
• Oral Disease-Modifying Treatments for Multiple Sclerosis

  2007cites this paper
• Immunosuppression: promises and failures.

  2007cites this paper
• Novel insights in the immune function of the vitamin D system: synergism with interferon-beta.

  2007cites this paper
• Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis

  2007cites this paper
• Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

  2007cites this paper
• [Multiple sclerosis and nephrotic syndrome in minimal change disease].

  2007cites this paper
• Basic immunosuppressive drugs outside solid organ transplantation

  2006cites this paper
• Imaging of multiple sclerosis: Role in neurotherapeutics

  2005cites this paper
• Other therapy options and future strategies for treating patients with multiple sclerosis

  2004cites this paper
• The dynamics of multiple sclerosis

  2004cites this paper
• Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures

  2004cites this paper
• Management of Secondary-Progressive Multiple Sclerosis

  2004cites this paper
• FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: Neuroimmunophilin ligand‐mediated neuroprotection in a model of multiple sclerosis

  2004cites this paper
• Remission of Multiple Sclerosis Post-Liver Transplantation

  2004cites this paper
• Current Disease-Modifying Therapies in Multiple Sclerosis

  2003cites this paper
• Mitoxantrone in progressive multiple sclerosis: when and how to treat?

  2003cites this paper
• A novel nitric oxide scavenger in combination with cyclosporine A ameliorates experimental autoimmune encephalomyelitis progression in mice.

  2003cites this paper
• Disease-modifying therapies for multiple sclerosis

  2003cites this paper
• The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis

  2003cites this paper
• [Immunosuppressants and multiple sclerosis].

  2002cites this paper
• [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: I. The evidences for the use of immunosuppressive agents, plasma exchange and autologous hematopoietic stem cell transplantation].

  2002cites this paper
• [Immunosuppressive medication in multiple sclerosis].

  2002cites this paper
• Impaired renal function in progressive multiple sclerosis

  2002cites this paper
• Immunotherapy of multiple sclerosis--current practice and future directions.

  2002cites this paper
• Medical hypothesis: why secondary progressive multiple sclerosis is a relentlessly progressive illness.

  2002cites this paper
• Cognitive dysfunction in multiple sclerosis: current approaches to clinical management

  2002cites this paper
• [Therapeutic indications targeting etiology of progressive multiple sclerosis].

  2001cites this paper
• Cyclosporin A treatment modulates cytokine mRNA expression by inflammatory cells extracted from the spinal cord of rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein.

  2001cites this paper
• A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.

  2001cites this paper
• [Cognitive impairment, clinic forms and progression in multiple sclerosis].

  2001cites this paper
• Pirfenidone for chronic progressive multiple sclerosis

  2001cites this paper
• Primary progressive multiple sclerosis

  2001cites this paper
• Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article].

  2001cites this paper
• MULTIPLE SCLEROSIS: NEW PATHOPHYSIOLOGICAL AND THERAPEUTIC CONCEPTS

  2001cites this paper
• Therapeutic developments in multiple sclerosis

  2000cites this paper
• [The natural history of multiple sclerosis].

  2000cites this paper
• Therapeutic apheresis in neurological disorders

  2000cites this paper
• Neuromuscular rehabilitation and electrodiagnosis. 1. Central neurologic disorders.

  2000cites this paper
• Treatment of secondary progressive multiple sclerosis: current recommendations and future prospects.

  1999cites this paper
• A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis

  1999cites this paper
• Multiple Sclerosis and Its Treatment

  1999cites this paper
• Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein.

  1999cites this paper
• Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

  1999cites this paper
• Immunologic therapy of multiple sclerosis.

  1999cites this paper
• Multiple sclerosis: Immunotherapy

  1999cites this paper
• A clinical review of drug-induced gingival overgrowths.

  1999cites this paper
• The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

  1999cites this paper
• Immunomodulating therapeutic approaches for multiple sclerosis.

  1998cites this paper
• A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases.

  1998cites this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cites this paper
• Current immunotherapy in multiple sclerosis

  1998cites this paper
• Safety and Tolerability of Subcutaneous Cladribine Therapy in Progressive Multiple Sclerosis

  1998cites this paper
• [Non-specific immunosuppression and multiple sclerosis].

  1998cites this paper
• A 21 Point Unifying Hypothesis on the Etiology and Treatment of Multiple Sclerosis

  1998cites this paper
• Svm~athetic Neural Mechanisms of CJyc~osporine-InducedHypertension

  1997cites this paper
• Nursing management of MS patients receiving interferon beta-1b therapy.

  1997cites this paper
• In vitro modulation of human, autoreactive MBP-specific CD4 + T-cell clones by cyclosporin A.

  1997cites this paper
• Rational clinical immunotherapy for multiple sclerosis.

  1997cites this paper
• Value of magnetic resonance imaging in assessing efficacy in clinical trials of multiple sclerosis therapies.

  1997cites this paper
• Management of multiple sclerosis.

  1997cites this paper
• Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells.

  1997cites this paper
• Clinical and Magnetic Resonance Imaging Changes Correlate in a Clinical Trial Monitoring Cyclosporine Therapy for Multiple Sclerosis

  1997cites this paper
• Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

  1997cites this paper
• Recommendations from the national multiple sclerosis society clinical outcomes assessment task force

  1997cites this paper
• Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis.

  1997cites this paper
• Indictment of the microglia as the villain in multiple sclerosis

  1997cites this paper
• Meta-analysis of the placebo-treated groups in clinical trials of progressive MS

  1996cites this paper